KalVista Pharmaceuticals (KALV) Competitors $13.21 -0.42 (-3.08%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$13.62 +0.41 (+3.13%) As of 08/1/2025 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KALV vs. CRNX, IMVT, ALVO, MOR, OGN, NAMS, RXRX, GMTX, RARE, and MIRMShould you be buying KalVista Pharmaceuticals stock or one of its competitors? The main competitors of KalVista Pharmaceuticals include Crinetics Pharmaceuticals (CRNX), Immunovant (IMVT), Alvotech (ALVO), MorphoSys (MOR), Organon & Co. (OGN), NewAmsterdam Pharma (NAMS), Recursion Pharmaceuticals (RXRX), Gemini Therapeutics (GMTX), Ultragenyx Pharmaceutical (RARE), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry. KalVista Pharmaceuticals vs. Its Competitors Crinetics Pharmaceuticals Immunovant Alvotech MorphoSys Organon & Co. NewAmsterdam Pharma Recursion Pharmaceuticals Gemini Therapeutics Ultragenyx Pharmaceutical Mirum Pharmaceuticals Crinetics Pharmaceuticals (NASDAQ:CRNX) and KalVista Pharmaceuticals (NASDAQ:KALV) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk. Do institutionals & insiders believe in CRNX or KALV? 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 4.6% of Crinetics Pharmaceuticals shares are owned by insiders. Comparatively, 10.5% of KalVista Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Does the media refer more to CRNX or KALV? In the previous week, Crinetics Pharmaceuticals and Crinetics Pharmaceuticals both had 4 articles in the media. Crinetics Pharmaceuticals' average media sentiment score of 0.88 beat KalVista Pharmaceuticals' score of -0.01 indicating that Crinetics Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive KalVista Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do analysts rate CRNX or KALV? Crinetics Pharmaceuticals presently has a consensus target price of $69.50, suggesting a potential upside of 149.64%. KalVista Pharmaceuticals has a consensus target price of $26.29, suggesting a potential upside of 98.98%. Given Crinetics Pharmaceuticals' higher probable upside, analysts plainly believe Crinetics Pharmaceuticals is more favorable than KalVista Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Crinetics Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.80KalVista Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.11 Which has preferable valuation & earnings, CRNX or KALV? KalVista Pharmaceuticals has lower revenue, but higher earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than KalVista Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCrinetics Pharmaceuticals$1.04M2,506.40-$298.41M-$3.82-7.29KalVista PharmaceuticalsN/AN/A-$183.44M-$3.69-3.58 Which has more risk and volatility, CRNX or KALV? Crinetics Pharmaceuticals has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.05, suggesting that its share price is 95% less volatile than the S&P 500. Is CRNX or KALV more profitable? Crinetics Pharmaceuticals' return on equity of -30.95% beat KalVista Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Crinetics PharmaceuticalsN/A -30.95% -28.12% KalVista Pharmaceuticals N/A -134.07%-82.65% SummaryCrinetics Pharmaceuticals beats KalVista Pharmaceuticals on 7 of the 13 factors compared between the two stocks. Get KalVista Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for KALV and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KALV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KALV vs. The Competition Export to ExcelMetricKalVista PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$680.87M$2.46B$5.49B$9.54BDividend YieldN/A1.81%4.73%4.09%P/E Ratio-3.588.9728.8323.83Price / SalesN/A437.65372.0766.02Price / CashN/A157.7635.4557.96Price / Book6.884.838.275.54Net Income-$183.44M$31.62M$3.25B$259.28M7 Day Performance-9.40%-5.28%-3.73%-4.68%1 Month Performance12.14%4.38%4.29%4.36%1 Year Performance0.30%-2.49%25.87%17.88% KalVista Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KALVKalVista Pharmaceuticals3.8282 of 5 stars$13.21-3.1%$26.29+99.0%-4.5%$680.87MN/A-3.58100CRNXCrinetics Pharmaceuticals3.3272 of 5 stars$30.30-2.2%$69.50+129.4%-46.5%$2.90B$1.04M0.00210News CoverageUpcoming EarningsIMVTImmunovant1.6706 of 5 stars$16.76-1.1%$36.40+117.2%-45.6%$2.90BN/A0.00120Upcoming EarningsALVOAlvotech3.3884 of 5 stars$9.81+2.1%$14.00+42.7%-24.0%$2.90B$491.98M16.571,032Positive NewsMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730OGNOrganon & Co.4.8732 of 5 stars$9.96-2.4%$18.00+80.7%-54.9%$2.65B$6.40B2.824,000Upcoming EarningsNAMSNewAmsterdam Pharma3.3287 of 5 stars$23.42-0.8%$41.30+76.3%+23.4%$2.65B$45.56M-12.464Positive NewsUpcoming EarningsRXRXRecursion Pharmaceuticals1.5365 of 5 stars$6.31-2.8%$7.00+10.9%-22.6%$2.64B$58.84M0.00400Upcoming EarningsGap DownGMTXGemini TherapeuticsN/A$60.61+0.0%N/A+38.5%$2.63BN/A-60.6130RAREUltragenyx Pharmaceutical4.4832 of 5 stars$27.61+1.0%$82.57+199.1%-35.6%$2.58B$560.23M-4.701,294Upcoming EarningsAnalyst RevisionMIRMMirum Pharmaceuticals3.7255 of 5 stars$51.49-0.7%$65.50+27.2%+29.6%$2.57B$336.89M0.00140News CoveragePositive NewsUpcoming Earnings Related Companies and Tools Related Companies CRNX Alternatives IMVT Alternatives ALVO Alternatives MOR Alternatives OGN Alternatives NAMS Alternatives RXRX Alternatives GMTX Alternatives RARE Alternatives MIRM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KALV) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredJeff Bezos Launches "ChatGPT Killer"?Amazon just launched Nova—its secretive new AI system designed to rival ChatGPT. Bezos says he now spends 95% ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding KalVista Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share KalVista Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KALV Stock Alerts